• Orthopoxvirus-Induced RIPK3 Degradation Modulates Inflammati

  2026-07-28

  Liu et al. (2021) reveal that orthopoxviruses encode a viral inducer of RIPK3 degradation (vIRD) which targets the necroptosis adaptor RIPK3 for SCF-mediated proteasomal degradation, thereby controlling virus-induced inflammation and replication. This discovery clarifies viral immune evasion strategies and highlights new targets for dissecting cell death pathways in infection and immunity.

• Spiroplasma eriocheiris Entry: Cytoskeletal Dependence in S2

  2026-07-28

  This study reveals that Spiroplasma eriocheiris invades Drosophila S2 cells via clathrin-mediated endocytosis and macropinocytosis, with a critical reliance on host microtubules and actin filaments. The findings clarify both the cellular entry mechanisms and the importance of cytoskeletal dynamics, informing future pathogen-host interaction research and cytoskeleton-targeted assays.

• Aurora Kinase A Overexpression in Retinoblastoma: Targeted T

  2026-07-27

  A recent study demonstrates that Aurora kinase A (AURKA) is significantly overexpressed in human retinoblastoma, correlating with high-risk histopathological features and poor chemotherapy response. These findings highlight the promise of AURKA as a targeted therapeutic avenue in advanced or refractory retinoblastoma, providing a foundation for the use of selective Aurora A inhibitors.

• Artesunate in Cancer Models: Protocol Insights & Innovations

  2026-07-27

  Artesunate, a semi-synthetic artemisinin derivative, is redefining in vitro cancer research through its dual action as a ferroptosis inducer and AKT/mTOR pathway inhibitor. This article unpacks optimized experimental workflows, practical troubleshooting, and strategic insights for deploying Artesunate in advanced oncology models, translating recent methodological breakthroughs into actionable guidance.

• Methylation and CNS Disorders: Insights from Ademetionine St

  2026-07-26

  This review synthesizes evidence on the clinical and biochemical significance of methylation, especially S-adenosylmethionine (SAMe), in neurological and psychiatric disorders. It details the role of methyl donor metabolism in CNS health and highlights potential avenues for therapeutic intervention.

• Live-Dead Bacterial Staining Kit: Viability Assay Innovation

  2026-07-25

  The Live-Dead Bacterial Staining Kit empowers researchers to precisely quantify bacterial viability in advanced infection and nanomaterial studies. By leveraging dual-dye fluorescence, this kit streamlines membrane integrity analysis and bridges translational gaps in microbiology research.

• AP-1 Inhibition Induces Ferroptosis in Myeloma via PI3K/AKT

  2026-07-24

  This study demonstrates that the C-Fos/AP-1 inhibitor T-5224 triggers ferroptosis in multiple myeloma cells by suppressing the PI3K/AKT pathway. These findings expand the understanding of T-5224’s mechanisms, highlighting its potential for combinatorial therapy and providing new insights into targeted cell death in hematological malignancy.

• Leucovorin Calcium: Advancing Methotrexate Rescue in Tumor M

  2026-07-24

  Leucovorin Calcium empowers researchers to precisely model methotrexate rescue and dissect antifolate drug resistance in complex assembloid systems. Its robust solubility and validated performance in patient-derived models make it indispensable for next-generation tumor–stroma interaction studies.

• Hydrocortisone: Glucocorticoid Hormone for Precision Models

  2026-07-23

  Hydrocortisone empowers researchers to dissect glucocorticoid receptor signaling, anti-inflammatory pathways, and neuroprotection in both cell and animal models. This guide delivers stepwise protocols, troubleshooting wisdom, and practical insights for maximizing reproducibility in inflammation and stress response studies.

• Myriocin: Applied Workflows for Sphingolipid Metabolism Rese

  2026-07-23

  Myriocin, a potent serine palmitoyltransferase inhibitor, enables precise dissection of sphingolipid metabolism and cell cycle regulation in cancer and immunology models. This guide details optimized experimental workflows, troubleshooting strategies, and actionable insights for leveraging Myriocin in advanced bench research.

• Regorafenib (BAY 73-4506): Mechanisms and Evidence in Cancer

  2026-07-22

  Regorafenib (BAY 73-4506) is an orally active multikinase inhibitor that disrupts angiogenesis and tumor progression by targeting VEGFRs, PDGFRβ, and RAF kinases. Recent evidence confirms its efficacy in suppressing melanoma growth through RRM2 downregulation and ERK/E2F3 pathway inhibition. This article details mechanistic insights, protocol parameters, and practical boundaries for researchers employing Regorafenib in cancer biology research.

• GM 6001 (Galardin): Broad-Spectrum MMP Inhibitor for ECM Res

  2026-07-22

  GM 6001 (Galardin) is a nanomolar-potency, broad-spectrum matrix metalloproteinase inhibitor used to dissect extracellular matrix remodeling in diverse disease and tissue models. It specifically inhibits MMP-1, MMP-2, MMP-3, MMP-8, and MMP-9 with high affinity. This dossier details its mechanisms, validated uses, and correct application in research workflows.

• Uncovering Fungal Diversity in Xyleborus affinis Mutualisms

  2026-07-21

  This study rigorously fulfills Koch-like postulates for animal-fungal mutualisms by isolating and validating several filamentous fungi and yeasts from the mycangia and galleries of Xyleborus affinis beetles. The findings reveal that omitting ethanol washing protocols uncovers greater symbiont diversity, impacting how these mutualisms are characterized and experimentally validated.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Technical Workflow

  2026-07-21

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody enables sensitive, specific detection of goat IgG primary antibodies in fluorescence-based immunodetection workflows, including ICC/IF, IHC, flow cytometry, and ELISA. It should only be used for detection of goat IgG in validated protocols; applications outside this scope or with non-goat primaries are not recommended due to potential off-target binding.

• TMEM16F Lipid Scrambling: A Ferroptosis Suppressor in Tumor

  2026-07-20

  Yang et al. reveal that TMEM16F-mediated lipid scrambling on the plasma membrane acts as a late-stage suppressor of ferroptosis, reducing membrane damage and modulating tumor cell fate. Their work demonstrates that inhibiting this pathway increases ferroptosis sensitivity and, when combined with PD-1 blockade, enhances tumor immune rejection, offering new mechanistic insights for cancer research.

11932 records 3/796 page Previous Next 12345 下5页 Last page